HowardPSafranMD

Oncology • Providence, RI

Associate Professor, Medicine, Brown University Program in Medicine

Join to view full profile

Dr. Safran is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Safran's full profile

Already have an account?

Office
164 Summit Ave
Fain 3
Providence, RI 02906
Phone+1 401-793-2920
Is this information wrong?

Education & Training

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1992
Boston University Medical CenterResidency, Internal Medicine, 1987 - 1990
Boston University School of MedicineClass of 1987

Certifications & Licensure

MA State Medical License 1989 - 2024
RI State Medical License 1993 - 2024
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top MD Consumers Checkbook

Clinical Trials

Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer Start of enrollment: 1998 Jan 01
Unknown status
Phase 2
Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas Start of enrollment: 1999 Mar 01
Unknown status
Phase 2
A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema Start of enrollment: 2006 Jul 01
Completed
Phase 1
Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer Start of enrollment: 2004 Oct 01
Completed
Phase 2
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer Start of enrollment: 2007 Mar 01
Terminated
Phase 1
Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001) Start of enrollment: 2007 Aug 01
Completed
Phase 2
Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial Start of enrollment: 2009 Jan 01
Completed
Phase 2
A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2009 Mar 01
Terminated
Phase 1
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
Active, not recruiting
Phase 3
RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer Start of enrollment: 2009 Dec 01
Terminated
Phase 1
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab Start of enrollment: 2010 Jul 01
Terminated
Phase 2
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer Start of enrollment: 2010 Sep 01
Terminated
Phase 1
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen Start of enrollment: 2011 Jun 01
Terminated
Phase 2
Cabazitaxel and Radiation For Patients With Prostate Cancer Start of enrollment: 2013 Jan 01
Terminated
Phase 2
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer Start of enrollment: 2012 Nov 01
Terminated
Phase 2
Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer Start of enrollment: 2012 Apr 01
Completed
Not Applicable
Adjuvant Aflibercept for Metastatic Colorectal Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 1, Phase 2
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma Start of enrollment: 2013 Mar 01
Terminated
Phase 2
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer Start of enrollment: 2012 May 01
Completed
Phase 1, Phase 2
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study Start of enrollment: 2012 Nov 01
Completed
Phase 1
Rectal Cancer Consortium Start of enrollment: 2013 Jul 01
Completed
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) Start of enrollment: 2013 May 01
Completed
Phase 2
BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial Start of enrollment: 2014 Feb 01
Completed
Phase 2
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin Start of enrollment: 2014 Jul 01
Terminated
Phase 2
BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial Start of enrollment: 2014 Aug 01
Completed
Phase 2
BGJ398 for Patients With Tumors With FGFR Genetic Alterations Start of enrollment: 2014 Jul 24
Terminated
Phase 2
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) Start of enrollment: 2014 Sep 17
Terminated
Phase 2
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25
Completed
Phase 2
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis Start of enrollment: 2013 May 01
Unknown status
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Start of enrollment: 2016 Feb 19
Completed
Phase 1
Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island Start of enrollment: 2020 Aug 28
Recruiting
Join now to see all

Publications & Presentations

PubMed

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
Davis, E., Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran, Wen Wee Ma, Andrew L Coveler, Steven Powell, Bruno Bastos, Eli...> ;Clinical Cancer Research. 2024 Feb 1
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT).
Purbhoo, M., Grossman, J., Buell, J., Hadfield, M., Safran, H., Carneiro, B.> ;Oncogene. 2024 Mar 1
Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848.
Leila T Tchelebi, Kathryn A Winter, Ross A Abrams, Howard P Safran, William F Regine, Susan McNulty, Abraham Wu, Kevin L Du, Samantha A Seaward, Shelly X Bian, Raid Al...> ;International Journal of Radiation Oncology, Biology, Physics. 2024 Jan 1
1 citations
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran, Laura Nadeau, William J Edenfield, Lionel D Lewis, Lone H Ottesen, Yan Li, Ganesh M Mu...> ;Cancer Chemotherapy and Pharmacology. 2023 Sep 1
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran, Laura Nadeau, William J Edenfield, Lionel D Lewis, Dinko Rekić, Corina Dota, Lone H Ot...> ;Cancer Chemotherapy and Pharmacology. 2023 Aug 1
Addendum:: a novel gene fusion in hepatic angiosarcoma.
Eric I Marks, Sahithi Pamarthy, Don Dizon, Ari Birnbaum, Evgeny Yakirevich, Howard Safran, Benedito A Carneiro> ;Oncotarget. 2023 May 26
2 citations
Clinical features of patients with-deleted bladder cancer.
Andre L De Souza, Anthony E Mega, John Douglass, Adam J Olszewski, Ece D Gamsiz Uzun, Alper Uzun, Charissa Chou, Fenghai Duan, Jinyu Wang, Amin Ali, Dragan J Golijanin...> ;American Journal of Cancer Research. 2023 Jan 1
4 citations
Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma.
Andrew Hsu, Kelsey E Huntington, Andre De Souza, Lanlan Zhou, Adam J Olszewski, Nirav P Makwana, Diana O Treaba, Ludimila Cavalcante, Francis J Giles, Howard Safran, W...> ;Cancer Biology & Therapy. 2022 Dec 31
2 citations
Objective Impact of Hematology-Oncology Hospitalist Care in an Inpatient Setting.
Kristina A Fanucci, Andrew Yang, Alison Chambers, Don Dizon, Howard Safran, Rabin Niroula> ;JCO Oncology Practice. 2022 Oct 1
1 citations
Long-term avelumab in advanced non-small-cell lung cancer: summaries andanalyses from JAVELIN Solid Tumor.
Borys Hrinczenko, Nicholas Iannotti, Sanjay Goel, David Spigel, Howard Safran, Matthew H Taylor, Jaafar Bennouna, Deborah J Wong, Karen Kelly, Claire Verschraegen, Mar...> ;Future Oncology. 2022 Apr 1
2 citations
Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies.
Yazmin Odia, Ludimila Cavalcante, Howard Safran, Steven Francis Powell, Pamela N Munster, Wen Wee Ma, Benedito A Carneiro, Bruno R Bastos, Stacy Mikrut, William Mikrut...> ;Neuro-Oncology Advances. 2022 Feb 7
44 citations
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.
Howard P Safran, Kathryn Winter, David H Ilson, Dennis Wigle, Thomas DiPetrillo, Michael G Haddock, Theodore S Hong, Lawrence P Leichman, Lakshmi Rajdev, Murray Resnic...> ;The Lancet. Oncology. 2022 Feb 1
3 citations
Oral administration of TRAIL-inducing small molecule ONC201/TIC10 prevents intestinal polyposis in themouse model.
Venkateshwar Madka, Arielle De La Cruz, Gopal Pathuri, Janani Panneerselvam, Yuting Zhang, Nicole Stratton, Sean Hacking, Niklas K Finnberg, Howard P Safran, Shizuko S...> ;American Journal of Cancer Research. 2022 Jan 1
7 citations
Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
Aakash Jhaveri, Lanlan Zhou, Marie D. Ralff, Young Lee, Arunasalam Navaraj, Benedito A. Carneiro, Howard Safran, Varun V. Prabhu, Eric A. Ross, Seul Ki Lee, Wafik S. E...> ;Cancer Biology & Therapy. 2021 Dec 2
22 citations
EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of mu...
Yiqun Zhang, Lanlan Zhou, Howard Safran, Robyn Borsuk, Rishi Lulla, Nikos Tapinos, Attila A. Seyhan, Wafik S. El-Deiry> ;Neoplasia. 2021 Jul 8
9 citations
Strategies to sensitize cancer cells to immunotherapy.
Andrew George, Ilyas Sahin, Benedito A. Carneiro, Don S. Dizon, Howard Safran, Wafik S. El-Deiry> ;Human Vaccines & Immunotherapeutics. 2021 May 21
2 citations
A Pilot Study of Short-course Nivolumab and Low-dose Ipilimumab for Adjuvant Treatment of Melanoma: Brown University Oncology Research Group Trial, BrUOG 324.
Maria Constantinou, Thomas J. Miner, John M Vatkevitch, Ali Naboush, Sopha Dionson, Jasmine Anderson, Taylor Kolvek, Maria Medeiros, Kelsey MacKinnon, Roxanne Wood, Ho...> ;American Journal of Clinical Oncology. 2021 Jun 1
4 citations
Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704.
Danielle S. Bitterman, Kathryn Winter, Theodore S. Hong, Charles S. Fuchs, William F. Regine, Ross A. Abrams, Howard Safran, John P. Hoffman, Al B. Benson, Timothy Kas...> ;International Journal of Radiation Oncology, Biology, Physics. 2021 Jan 1
4 citations
The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer
Brittany A. Borden, Yasmine Baca, Joanne Xiu, Fabio Tavora, Ira Winer, Benjamin A. Weinberg, Ari M. Vanderwalde, Sourat Darabi, W. Michael Korn, Andrew P. Mazar, Franc...> ;Molecular Cancer Therapeutics. 2021 Jan 1
4 citations
Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.
Eric I Marks, Robert Matera, Adam J. Olszewski, Evgeny Yakirevich, Wafik S. El-Deiry, Howard Safran, Benedito A. Carneiro> ;American Journal of Clinical Oncology. 2021 Feb 1
5 citations
Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
Heinrich Elinzano, Steven A. Toms, Jordan Robison, Alex B. Mohler, Arieana B. Carcieri, Deus Cielo, Jennifer Donnelly, Dylan Disano, John Vatketich, John Baekey, Ashle...> ;American Journal of Clinical Oncology. 2021 Feb 1
4 citations
Adjuvant FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer: A Brown University Oncology Research Group Phase II Study (BrUOG295).
Alexander G Raufi, Rimini Breakstone, Kara L. Leonard, Kevin P. Charpentier, Rachel E. Beard, Jennifer Renaud, Lindsey Cavanaugh, Ashlee Sturtevant, Kelsey MacKinnon, ...> ;American Journal of Clinical Oncology. 2020 Dec 1
18 citations
MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 i...
Lanlan Zhou, Kelsey E. Huntington, Shengliang Zhang, Lindsey Carlsen, Eui Young So, Cassandra Parker, Ilyas Sahin, Howard Safran, Suchitra Kamle, Chang-Min Lee, Chun G...> ;Oncotarget. 2020 Nov 17
112 citations
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVE...
Markus Moehler, Mikhail Dvorkin, Narikazu Boku, Mustafa Ozguroglu, Min Hee Ryu, Alina Muntean, Sara Lonardi, Marina Nechaeva, Arinilda Silva Campos Bragagnoli, Hasan Ş...> ;Journal of Clinical Oncology. 2020 Nov 16
78 citations
ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Varun V. Prabhu, Sara Morrow, Abed Rahman Kawakibi, Lanlan Zhou, Marie D. Ralff, Jocelyn E. Ray, Aakash Jhaveri, Isacco Ferrarini, Young Lee, Cassandra Parker, Yiqun Z...> ;Neoplasia. 2020 Oct 23
Join now to see all

Lectures

Glycogen synthase kinase-3 beta (GSK-3β) blockade with 9-ing-41 in gastrointestinal cancers: The 1801 phase Ib/II study.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
Adjuvant FOLFOX + nab-paclitaxel (FOLFOX-A)for pancreatic cancer, BrUOG 278: A Brown University oncology research group phase II study.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Working to Close the Cancer Screening Gap Caused by COVIDMay 17th, 2022
Dana-Farber Cancer Institute and Lifespan Renew Strategic Alliance AgreementMarch 23rd, 2022
Trastuzumab Combined with Trimodality Treatment for HER2-Overexpressing Esophageal Cancer Found to Be IneffectiveJanuary 22nd, 2022
Join now to see all